Ferreira, João Pedro http://orcid.org/0000-0002-2304-6138
Cleland, John G.
Lam, Carolyn S. P.
Anker, Stefan D.
Mehra, Mandeep R.
van Veldhuisen, Dirk J.
Byra, William M.
La Police, David A.
Pitt, Bertram
Greenberg, Barry
Zannad, Faiez
Article History
Received: 3 January 2021
Accepted: 24 February 2021
First Online: 8 March 2021
Declarations
:
: Dr Ferreira is a consultant for Boehringer-Ingelheim. Dr Zannad reports steering committee personal fees from Applied Therapeutics, Amgen, Bayer, Boehringer, Novartis, Janssen, Cellprothera and CVRx, advisory board personal fees from, AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmaceutical, Corvidia, Merck, Myokardia, NovoNordisk and Owkin, stock options at Cereno and G3Pharmaceutical, and being the founder of the Global Cardiovascular Clinical Trialist Forum. Dr Lam has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC; and serves as co-founder & non-executive director of Us2.ai. Dr Greenberg reports consulting fees from Amgen, Cytokinetics, EBR Systems, Impulse Dynamics, Ionis, Jaan, Janssen, Merck, Myokardia, Sanofi, Vifor, Viking, Windtree and Zensun. All the other authors report not having relevant conflicts of interest regarding the content of this manuscript.